Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-24

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Genomic Medicine for Ill Neonates and Infants (The GEMINI Study) is a research study aimed at comparing the clinical and economic utility of performing rapid whole genomic sequencing versus a targeted genomic sequencing panel on neonates and infants suspected of having a genetic disorder. This study is funded by the National Institutes of Health.

This multicenter, prospective clinical trial will enroll 400 subjects at the Floating Hospital for Children at Tufts Medical Center (Boston, MA), Cincinnati Children's Hospital Medical Center (Cincinnati, OH), Mount Sinai Kravis Children's Hospital (New York, NY), North Carolina Children's Hospital (Chapel Hill, NC), Children's Hospital of Pittsburgh (Pittsburgh, PA), and Rady Children's Hospital (San Diego, CA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genomic Uniformed-Screening Against Rare Disease In All Newborns

NCT05990179

Early Onset Genetic Conditions With Near Complete Penetrance

RECRUITING NA

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants

NCT05161169

Genetic Predisposition to Disease Hereditary Diseases

COMPLETED NA

Genomic Sequencing for Childhood Risk and Newborn Illness

NCT02422511

Hereditary Disease Genetic Predisposition to Disease

COMPLETED NA

Multicenter Analysis of Genomic and Metabolic Data of Neonatal Genetic Diseases

NCT06183138

Hereditary Diseases

RECRUITING

North Carolina Newborn Exome Sequencing for Universal Screening

NCT02826694

Metabolism, Inborn Errors Hearing Loss Hereditary Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter, prospective clinical trial will examine the diagnostic yield and clinical utility of NewbornDx, a targeted genomic sequencing panel for use in the neonate, and rapid whole genomic sequencing (rWGS) testing in high-risk infants with signs/symptoms consistent with a possible genetic disorder. Infants will undergo NewbornDx and rWGS (proband) testing. The biological parent(s), when available, will undergo NewbornDx testing at the same time as the infant. For rWGS,the infant will undergo testing first. If a specific diagnosis that is consistent with the phenotype is not made with rWGS proband analysis alone, the parent(s) will undergo rWGS. The study will also evaluate the cost effectiveness of each test as well as standard of care (SOC) testing. A retrospective chart review of infants with suspected genetic disorders will be done to understand 1-year cost and health outcomes that would have been incurred in the absence of the advanced testing. The resulting data from the trial will be used in the economic evaluation comparing NewbornDx, rWGS, and SOC over a 1-year period and used as basis to simulate the lifetime cost-effectiveness of these testing strategies. A web-based clinical reference database to provide references, clinical management guidelines, opportunities for clinical trial participation, and support groups for each condition will be developed with separate interfaces for the parent/guardian(s) and medical provider. The clinical reference database will be qualitatively assessed by a survey of medical providers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric: Genetic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Group - All participants underwent both rGS and NewbornDx.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients receiving genetic testing in the NICU

The study included 400 probands, 388 mothers, and 316 fathers who participated

Group Type EXPERIMENTAL

rapid whole genomic sequencing (rWGS)

Intervention Type DIAGNOSTIC_TEST

rWGS and NewbornDx are genomic sequencing platforms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rapid whole genomic sequencing (rWGS)

rWGS and NewbornDx are genomic sequencing platforms

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NewbornDx

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented informed consent from the parent/guardian
* Signs/symptoms consistent with a possible genetic disorder
* Admitted to a hospital participating in this study at the time of enrollment
* Less than one year corrected gestational age

Exclusion Criteria

* A known genetic diagnosis (e.g. prenatal testing)
* Major congenital anomaly associated with a chromosomal anomaly detected on prenatal testing
* Presence of documented congenital infection
* Infants considered non-viable due to prematurity (\< 23 0/7 weeks GA)

Minimum Eligible Age

1 Day

Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No